Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

Verrica Pharmaceuticals (Nasdaq: VRCA), a dermatology therapeutics company, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference. The company's President and CEO, Jayson Rieger, PhD, MBA, will engage in a fireside chat during the event.

The virtual presentation is scheduled for Tuesday, April 8, 2025, at 1:30 pm ET. Interested participants can access the live webcast through a provided link or via the Investors/Presentations & Events section on Verrica's website. The webcast recording will remain available for 90 days after the event, which runs from April 7-10, 2025.

WEST CHESTER, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will participate in a fireside chat at the 24^th Annual Needham Virtual Healthcare Conference.

24^th Annual Needham Virtual Healthcare Conference, April 7-10, 2025
Event details:
Date: Tuesday, April 8, 2025
Time: 1:30 pm ET
Location: Virtual

Participants may access a live webcast of the event by clicking the link here.

The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com. A replay of the webcast will be posted shortly after the presentation and will be available for 90 days following the event.

About Verrica Pharmaceuticals Inc. 
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s product YCANTH^® (VP-102) (cantharidin), is the first and only commercially available treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH^® (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (formerly LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit www.verrica.com.

FOR MORE INFORMATION, PLEASE CONTACT:
Investors:

John J Kirby 
Interim Chief Financial Officer 
jkirby@verrica.com

Kevin Gardner 
LifeSci Advisors 
kgardner@lifesciadvisors.com

FAQ

When is Verrica Pharmaceuticals (VRCA) presenting at the Needham Healthcare Conference 2025?

Verrica Pharmaceuticals will present on Tuesday, April 8, 2025, at 1:30 pm ET during the virtual conference.

How can investors watch Verrica's (VRCA) Needham Conference presentation?

Investors can access the live webcast through a direct link or the Investors/Presentations & Events section on www.verrica.com.

How long will Verrica's (VRCA) Needham Conference presentation replay be available?

The webcast replay will be available for 90 days following the event.

Who is presenting for Verrica Pharmaceuticals (VRCA) at the 2025 Needham Conference?

Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will participate in a fireside chat.